// App-Quantinova.ai

604 : Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.

Researchers

Presenter

  • Lee Steven Schwartzberg

Principal Investigators

  • Kurt W. Tauer

  • Robert C. HermAnn Petros G. Nikolinakos

  • Arthur C. Houts

Medical Centers

  • The West Clinic and ACORN Research, LLC, Memphis, TN

  • Northeast Georgia Cancer Care, Athens, GAThe West Clinic, Memphis, TNACORN Research, LLC, Memphis, TN

  • Northwest Georgia Oncology Centers, Marietta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Breast cancer

  • Neutropenia

  • Peripheral neuropathy

  • Solid malignancies

  • Anemia

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Eribulin

  • Carboplatin

  • Trastuzumab

Outcome

  • Negative

Study Design

  • single arm

Phase

  • I/II

Study Id's

  • NCT01388647

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved